Elotuzumab, lenalidomide and panobinostat are now listed in the interaction checker as cancer drugs and interactions can be found with all the comedications.
- Elotuzumab (Emplicti®) is a SLAMF7-directed antibody and is indicated for the treatment of multiple myeloma.
- Lenalidomide (Revlimid®) is an immunomodulatory agent and is indicated for the treatment of multiple myeloma and mantle-cell lymphoma.
- Panobinostat (Farydak®) is a HDAC inhibitor and is indicated for the treatment of multiple myeloma.
